NASDAQ:VBLT - Vascular Biogenics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vascular Biogenics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.20 -0.04 (-3.23 %) (As of 04/3/2020 03:26 PM ET) Add Compare Today's Range$1.20Now: $1.20▼$1.2150-Day Range$0.99MA: $1.29▼$1.4952-Week Range$0.90Now: $1.20▼$1.71Volume1,201 shsAverage Volume255,033 shsMarket Capitalization$43.06 millionP/E RatioN/ADividend YieldN/ABeta1.1 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VBLT Previous SymbolNASDAQ:VBLX CUSIPN/A CIK1603207 Webhttp://www.vblrx.com/ Phone972-8993-5000Debt Debt-to-Equity Ratio0.06 Current Ratio4.33 Quick Ratio4.33Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$560,000.00 Price / Sales76.89 Cash FlowN/A Price / Cash FlowN/A Book Value$1.00 per share Price / Book1.20Profitability EPS (Most Recent Fiscal Year)($0.54) Net Income$-19,460,000.00 Net Margins-3,462.10% Return on Equity-45.23% Return on Assets-35.50%Miscellaneous Employees39 Outstanding Shares35,880,000Market Cap$43.06 million Next Earnings Date5/20/2020 (Estimated) OptionableOptionable Receive VBLT News and Ratings via Email Sign-up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VBLT Rates by TradingView Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions How has Vascular Biogenics' stock been impacted by COVID-19 (Coronavirus)? Vascular Biogenics' stock was trading at $1.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VBLT stock has decreased by 1.6% and is now trading at $1.20. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Vascular Biogenics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vascular Biogenics. When is Vascular Biogenics' next earnings date? Vascular Biogenics is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Vascular Biogenics. How were Vascular Biogenics' earnings last quarter? Vascular Biogenics Ltd (NASDAQ:VBLT) issued its quarterly earnings results on Thursday, March, 19th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.03. The biopharmaceutical company had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.18 million. Vascular Biogenics had a negative return on equity of 45.23% and a negative net margin of 3,462.10%. View Vascular Biogenics' earnings history. What price target have analysts set for VBLT? 5 Wall Street analysts have issued 12-month price targets for Vascular Biogenics' stock. Their forecasts range from $2.00 to $3.25. On average, they expect Vascular Biogenics' stock price to reach $2.75 in the next twelve months. This suggests a possible upside of 129.2% from the stock's current price. View analysts' price targets for Vascular Biogenics. What are Wall Street analysts saying about Vascular Biogenics stock? Here are some recent quotes from research analysts about Vascular Biogenics stock: 1. According to Zacks Investment Research, "Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. " (3/28/2020) 2. Chardan Capital analysts commented, "We understand the colon cancer trial will be a single- arm open label design, providing the possibility of an early look at efficacy signals, with data anticipated in 2020. We expect more details on these programs as the GBM and colon cancer trials begin." (5/16/2019) Has Vascular Biogenics been receiving favorable news coverage? News articles about VBLT stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Vascular Biogenics earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutVascular Biogenics. Are investors shorting Vascular Biogenics? Vascular Biogenics saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 35,800 shares, a decrease of 29.5% from the February 27th total of 50,800 shares. Based on an average trading volume of 59,000 shares, the short-interest ratio is currently 0.6 days. Approximately 0.2% of the company's stock are short sold. View Vascular Biogenics' Current Options Chain. Who are some of Vascular Biogenics' key competitors? Some companies that are related to Vascular Biogenics include Protagonist Therapeutics (PTGX), Abeona Therapeutics (ABEO), Recro Pharma (REPH), Selecta Biosciences (SELB), Scpharmaceuticals (SCPH), Mallinckrodt (MNK), VBI Vaccines (VBIV), Osmotica Pharmaceuticals (OSMT), Hookipa Pharma (HOOK), IVERIC bio (ISEE), Ovid Therapeutics (OVID), MEI Pharma (MEIP), Spero Therapeutics (SPRO), Endonovo Therapeutics (ENDV) and LifeVantage (LFVN). What other stocks do shareholders of Vascular Biogenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Alibaba Group (BABA), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), vTv Therapeutics (VTVT), AEterna Zentaris (AEZS), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Opko Health (OPK) and Corbus Pharmaceuticals (CRBP). Who are Vascular Biogenics' key executives? Vascular Biogenics' management team includes the following people: Prof. Dror Harats, CEO & Director (Age 62)Mr. Amos Ron, CFO & Company Sec. (Age 64)Dr. Erez Feige, VP of Bus. Operations (Age 45)Dr. Eyal Breitbart, VP of Research & Operations (Age 52)Dr. Naamit Sher, VP of Drug Devel. & Regulatory Affairs (Age 65) What is Vascular Biogenics' stock symbol? Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT." How do I buy shares of Vascular Biogenics? Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Vascular Biogenics' stock price today? One share of VBLT stock can currently be purchased for approximately $1.20. How big of a company is Vascular Biogenics? Vascular Biogenics has a market capitalization of $43.06 million and generates $560,000.00 in revenue each year. The biopharmaceutical company earns $-19,460,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Vascular Biogenics employs 39 workers across the globe. View additional information about Vascular Biogenics. What is Vascular Biogenics' official website? The official website for Vascular Biogenics is http://www.vblrx.com/. How can I contact Vascular Biogenics? Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at 972-8993-5000 or via email at [email protected] MarketBeat Community Rating for Vascular Biogenics (NASDAQ VBLT)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 259 (Vote Outperform)Underperform Votes: 295 (Vote Underperform)Total Votes: 554MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote "Outperform" if you believe VBLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBLT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/3/2020 by MarketBeat.com StaffFeatured Article: What is the Euro STOXX 50 Index?
